相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Programmed cell death 1 ligand 1 signals in cancer cells
Anand V. R. Kornepati et al.
NATURE REVIEWS CANCER (2022)
Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells
S. Hua et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma
Jianfeng Guo et al.
MOLECULAR CANCER (2021)
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy
Xiaoli Hu et al.
MOLECULAR THERAPY (2021)
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects
Vivek Verma et al.
NATURE IMMUNOLOGY (2021)
Biological significance of KRAS mutant allele expression in ovarian endometriosis
Nozomi Yachida et al.
CANCER SCIENCE (2021)
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy
Deyi Zhang et al.
CANCER MEDICINE (2021)
Chlorambucil-Chitosan Nano-Conjugate: An Efficient Agent Against Breast Cancer Targeted Therapy
Azadeh Shayegh et al.
CURRENT DRUG DELIVERY (2021)
IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer
Suzanne R. Thibodeaux et al.
CLINICAL CANCER RESEARCH (2021)
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR
Soma Ghosh et al.
CELL REPORTS (2021)
The cGAS-STING pathway as a therapeutic target in inflammatory diseases
Alexiane Decout et al.
NATURE REVIEWS IMMUNOLOGY (2021)
PD-L1 regulates genomic stability via interaction with cohesin-SA1 in the nucleus
Wen Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hidetoshi Hayashi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
Recent Findings in the Posttranslational Modifications of PD-L1
Shu-Man Li et al.
JOURNAL OF ONCOLOGY (2020)
Regulation of sister chromatid cohesion by nuclear PD-L1
Jia Yu et al.
CELL RESEARCH (2020)
Merkel cell carcinoma in chronic lymphocytic leukemia Successful treatment with PD-L 1 inhibition, avelumab and chlorambucil
P. Duecker et al.
HAUTARZT (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy
Jiyong Liang et al.
CANCER IMMUNOLOGY RESEARCH (2020)
PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells
Na Song et al.
MEDICAL ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials
Hossein Borghaei et al.
CANCER (2020)
CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade
Justin M. Drerup et al.
CANCER RESEARCH (2020)
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
Yang Gao et al.
NATURE CELL BIOLOGY (2020)
PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis
Junwei Hou et al.
NATURE CELL BIOLOGY (2020)
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Han Yao et al.
NATURE BIOMEDICAL ENGINEERING (2019)
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation
Liang Deng et al.
ONCOGENE (2019)
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer et al.
FRONTIERS IN IMMUNOLOGY (2019)
BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts
Daofu Feng et al.
ONCOGENE (2019)
Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine
Hiro Sato et al.
CANCER SCIENCE (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Arun Rajan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine
Victoria D. Turubanova et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer
Shuo Wang et al.
FEBS LETTERS (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Yiting Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation
Frank P. Vendetti et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses
Rafael Cubas et al.
JOURNAL OF IMMUNOLOGY (2018)
Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
Bogang Wu et al.
ONCOIMMUNOLOGY (2018)
The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
Juri Ogishima et al.
BMC CANCER (2018)
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Yaxiong Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunogenic effects of chemotherapy-induced tumor cell death
Yi-Jun Wang et al.
GENES & DISEASES (2018)
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
Xiaosheng Wu et al.
HELIYON (2018)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
Curtis A. Clark et al.
CANCER RESEARCH (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer
Harshita B. Gupta et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)
CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells
Margaret Gil et al.
JOURNAL OF IMMUNOLOGY (2014)
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Laurence Zitvogel et al.
CLINICAL CANCER RESEARCH (2010)
分享论文
